Related Experiment Video
Updated: May 7, 2026
18:46
Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement
Sanyog Jain1, Jagadish M Sharma, Ashish K Agrawal
1Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali, Punjab 160062, India. sanyogjain@niper.ac.in
Journal of Biomedical Nanotechnology
|September 25, 2013
Summary
Surface stabilized efavirenz nanoparticles (EFZ-NPs) significantly enhance oral bioavailability. These novel nanoparticles show improved solubility, dissolution, and pharmacokinetic profiles compared to free efavirenz.
Area of Science:
- Pharmaceutical Nanotechnology
- Drug Delivery Systems
Background:
- Efavirenz (EFZ) is a crucial antiretroviral drug with poor oral bioavailability.
- Enhancing EFZ oral bioavailability is essential for improving patient compliance and therapeutic efficacy.
Purpose of the Study:
- To develop surface-stabilized efavirenz nanoparticles (EFZ-NPs) for enhanced oral bioavailability.
- To characterize the physicochemical properties, stability, and in vitro/in vivo performance of EFZ-NPs.
Main Methods:
- EFZ-NPs prepared using anti-solvent precipitation and high-pressure homogenization with hydroxypropyl methylcellulose stabilizer.
- Nanoparticles freeze-dried with trehalose cryoprotectant.
- Characterization included particle size, distribution, stability studies, solubility, in vitro dissolution, and in vivo pharmacokinetic evaluation.
Main Results:
- EFZ-NPs achieved an average particle size of ~350 nm with excellent distribution (<0.2).
- Nanoparticles exhibited enhanced saturation solubility (5.16-fold increase) and rapid in vitro dissolution (>75% in 5 min).
- In vivo studies showed a 2.02-fold increase in peak plasma concentration and a 2.29-fold increase in AUC(0-infinity) compared to free EFZ.
Conclusions:
- Surface-stabilized EFZ-NPs demonstrate superior stability and significantly improved oral bioavailability.
- The developed nanoparticles offer a promising strategy for enhancing the therapeutic efficacy of efavirenz.
- High in vitro-in vivo correlation (0.9995) validates the predictive power of dissolution studies for EFZ-NPs.
Related Concept Videos
01:16Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are employed to...